



High-Sensitivity Lateral Flow Assays for SARS-CoV-2 and Other Infections Volume II

Guest Editor:

Dr. Hideya Kawasaki

Institute for NanoSuit Research,
Preeminent Medical Photonics
Education & Research Center,
Hamamatsu University School of
Medicine, Hamamatsu, Shizuoka,
Japan

Deadline for manuscript
submissions:

31 May 2024

Message from the Guest Editor

Dear Colleagues,

Point-of-care testing (POCT) is applicable to a variety of areas of medicine and can make a significant difference in patient care. Lateral flow assays (LFAs) are critical in POCT. An LFA is a simple-to-use piece of diagnostic equipment that is used to confirm the presence or absence of a target analyte, such as SARS-CoV-2 or other infective agents, biomarkers in humans or animals, or pollutants in drinking water, food, or animal feed; however, its clinical utility has been questioned due to its limited sensitivity. Numerous strategies are used to improve sensitivity and quantitative detection, e.g., employing several visualization methods, using different labeling reporters, and integrating LFAs into other detection methods, resulting in their benefiting from both LFAs and the advantages of integrated detection devices for SARS-CoV-2 or other infections. This Special Issue invites submissions of novel and innovative original studies as well as comprehensive reviews on this topic.

- lateral flow assay
- point-of-care testing
- SARS-CoV-2
- high sensitivity
- detection device
- labeling reporters
- antigens
- pathogens





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)